Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: WJOG9717L Study
Hirotsugu Kenmotsu, Kazushige Wakuda, Keita Mori, Terufumi Kato, Shunichi Sugawara, Keisuke Kirita, Yasuto Yoneshima, Koichi Azuma, Kazumi Nishino, Shunsuke Teraoka, Takehito Shukuya, Ken Masuda, Hidetoshi Hayashi, Ryo Toyozawa, Satoru Miura, Daichi Fujimoto, Kazuhiko Nakagawa, Nobuyuki Yamamoto, Toshiaki Takahashi
Topics & Concepts
OsimertinibMedicineBevacizumabInternal medicineHazard ratioOncologyClinical endpointPneumonitisConfidence intervalLung cancerPhases of clinical researchRandomized controlled trialSurgeryChemotherapyEpidermal growth factor receptorCancerLungErlotinibLung Cancer Treatments and MutationsColorectal Cancer Treatments and StudiesInterstitial Lung Diseases and Idiopathic Pulmonary Fibrosis